Umeclidinium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 239 publications
Breztri Aerosphere for asthma.
Journal: The Medical letter on drugs and therapeutics
Published: June 25, 2026
Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: June 25, 2026
A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis.
Journal: Health technology assessment (Winchester, England)
Published: February 09, 2026
Optimizing COPD management in Latin America: a cost-effectiveness analysis of FF/UMEC/VI in Colombia.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: December 11, 2025
Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?
Journal: Journal of clinical medicine
Published: December 10, 2025
Cardiovascular events in patients with COPD after long-acting bronchodilator initiation.
Journal: ERJ open research
Published: November 28, 2025
Mining of Adverse Event Signals Associated with Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS.
Journal: Pharmacy (Basel, Switzerland)
Published: October 24, 2025
Long-Acting Muscarinic Antagonists for the Treatment of Difficult-to-Treat and Severe Asthma: A Narrative Review Focusing on Inflammation from Bench to Bedside.
Journal: Journal of inflammation research
Published: October 02, 2025
Efficacy and Safety of Topical Anticholinergics in the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-analysis.
Journal: Clinical drug investigation
Published: October 02, 2025
Long-acting β2 agonist (LABA) with a long-acting muscarinic receptor antagonist (LAMA) promotes human airway smooth muscle (HASM) relaxation and circumvents β2 adrenergic receptor tachyphylaxis.
Journal: Respiratory research
Published: September 23, 2025
Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial.
Journal: The journal of allergy and clinical immunology. Global
Published: September 19, 2025
TETRIS - Prospective study to observe clinical outcomes of triple therapy in COPD patients: Up to 12 months interim analysis.
Journal: Respiratory medicine
Published: August 19, 2025
Last Updated: 09/26/2026